Literature DB >> 5556280

Bretylium tosylate in the management of refractory ventricular fibrillation.

R W Dhurandhar, S J Teasdale, W A Mahon.   

Abstract

Nine patients who had recurrent ventricular fibrillation following acute myocardial infarction or angina were given bretylium tosylate in a dose of 5 mg./kg. intramuscularly every eight hours after other measures had proved ineffective. Provided the patients were not in shock or in heart failure, there was a considerable reduction in the episodes of ventricular fibrillation.A second group of nine patients who developed recurrent ventricular fibrillation following open heart surgery were given bretylium intravenously, which controlled the arrhythmia in every instance.Bretylium did not completely abolish ventricular premature beats but the latter did not initiate ventricular fibrillation even when they occurred on the T wave.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5556280      PMCID: PMC1930955     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  7 in total

1.  A mobile intensive-care unit in the management of myocardial infarction.

Authors:  J F Pantridge; J S Geddes
Journal:  Lancet       Date:  1967-08-05       Impact factor: 79.321

2.  Ventricular fibrillation complicating acute myocardial infarction.

Authors:  D M Lawrie; M R Higgins; M J Godman; M F Oliver; D G Julian; K W Donald
Journal:  Lancet       Date:  1968-09-07       Impact factor: 79.321

Review 3.  The clinical pharmacology and therapeutic applications of the antiarrhythmic drugs.

Authors:  D T Mason; J F Spann; R Zelis; E A Amsterdam
Journal:  Clin Pharmacol Ther       Date:  1970 Jul-Aug       Impact factor: 6.875

4.  Bretylium tosylate for suppression of induced ventricular fibrillation.

Authors:  M Bacaner
Journal:  Am J Cardiol       Date:  1966-04       Impact factor: 2.778

5.  The effect of bretylium on intracellular cardiac action potentials in relation to its anti-arrhythmic and local anaesthetic activity.

Authors:  J G Papp; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1969-10       Impact factor: 8.739

6.  The mode of action of quinidine on isolated rabbit atria interpreted from intracellular potential records.

Authors:  E M VAUGHAN WILLIAMS
Journal:  Br J Pharmacol Chemother       Date:  1958-09

7.  Bretylium tosylate in prevention of cardiac dysrhythmias after myocardial infarction.

Authors:  S H Taylor; C Saxton; P S Davies; J B Stoker
Journal:  Br Heart J       Date:  1970-05
  7 in total
  3 in total

1.  Potassium channel blockade: A mechanism for suppressing ventricular fibrillation.

Authors:  M B Bacaner; J R Clay; A Shrier; R M Brochu
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

2.  Bretylium and dobutamine in the treatment of coronary artery disease.

Authors:  W H Frishman
Journal:  Bull N Y Acad Med       Date:  1979-09

Review 3.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.